A novel AI-based fusion software for US/MR guided prostate biopsy: initial results

In a study conducted over several years, MRI-US fusion biopsies were performed using the Esaote UroFusion system, which incorporates AI-powered tools to enhance prostate segmentation and cancer detection. Some mpMRI scans initially conducted at external centers by non-specialist radiologists were re-evaluated by expert radiologists to ensure consistent and accurate lesion characterization. Adjustments were made to standardize evaluations and exclude cases without clear lesions. Lesion identification and confirmation benefited from the expertise of dedicated radiologists, highlighting the importance of specialized evaluations. The majority of confirmed lesions were clinically significant, and cancer detection rates were higher when using MRI-US fusion biopsies compared to systematic biopsy alone. However, systematic biopsy remained an essential component, as it identified additional clinically significant tumors not detected through targeted methods. The study underscores the importance of having mpMRI evaluations performed by expert radiologists to ensure better lesion characterization and diagnostic accuracy. AI-powered tools like UroFusion improve efficiency and detection rates, but systematic biopsy continues to play a critical role in comprehensive prostate cancer diagnosis. Collaboration between radiologists, urologists, and other specialists is vital for achieving optimal outcomes in the diagnosis and treatment of prostate cancer.